clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2022-100-11-12-509-519clinmed-464Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЛечение больных перикардитом противовоспалительными средствамиTreatment of patients with pericarditis with anti-inflammatory drugshttps://orcid.org/0000-0002-7858-7820СукмароваЗ. Н.SukmarovaZ. N.

Сукмарова Зульфия Наилевна— канд. мед. наук, научный сотрудник лаборатории системной красной волчанки

115522, Москва

Sukmarova Zulfiya N.

115522, Moscow

suzulfia@gmail.comСимоненкоВ. Б.SimonenkoV. B.

Симоненко Владимир Борисович — д-р мед. наук, профессор, член-корреспондент РАН, профессор кафедры терапии неотложных состояний

107392, Москва

Simonenko Vladimir B.

107392, Moscow

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

Насонов Евгений Львович — д-р мед. наук, профессор, академик РАН, научный руководитель; профессор кафедры внутренних, профессиональных болезней и ревматологии Института клинической медицины им. Н.В. Склифосовского; главный внештатный специалист-ревматолог МЗ РФ

115522, Москва119991, Москва

Nasonov Evgeny L.

115522, Moscow119991 Moscow

ФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой» Минздрава РоссииРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФилиал ФГБВОУ ВО Военно-медицинской академии им. С.М. Кирова в г. Москве, Минобороны РоссииРоссияBranch Military Medical Academy named after S.M. Kirov in Moscow of the Ministry of Defense of the RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии имени В.А. Насоновой» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation20221701202310011-12509519Copyright © Сукмарова З.Н., Симоненко В.Б., Насонов Е.Л., 20232023Сукмарова З.Н., Симоненко В.Б., Насонов Е.Л.Sukmarova Z.N., Simonenko V.B., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/464

С момента обновления Европейских рекомендаций по ведению перикардита [1] прошло 8 лет, почти 3 года из которых продолжается пандемия нового коронавируса, изменившего структуру и течение всех кардиологических заболеваний. На сегодняшний день нет сомнений, что доминирующей причиной возникновения перикардита является новый коронавирус SARS-CоV-2. Однако остаются актуальными такие неинфекционные причины, как системные воспалительные заболевания, паранеопластические и постперикардиотомные синдромы, требующие дифференцированной терапевтической стратегии. Для лучшего понимания параметров выбора лечебной схемы в систематическом обзоре рассматривается патогенез развития перикардита с учетом современных представлений об инфекционных и иммунных механизмах, а также высокой вероятности присоединения вируса SARS-CoV-2 к всем остальным имеющимся причинам. Особое внимание уделяется публикациям о диагностике в условиях пандемии и эффективности схем терапии перикардита при воспалении структур сердца, ассоциированных с COVID-19. Проведен обзор литературы в медицинских ресурсах PubMed, Google Scholar, UpToDate с давностью публикаций с 01.1990 по 09.2022 г., затрагивающих вопросы дифференцированной терапии перикардита различными противовоспалительными препаратами.

Eight years have passed since the update of the European recommendations for the management of pericarditis [1], and the pandemic of the new coronavirus continues for about 3 years of the period. It has changed the structure and course of all cardiovascular diseases. At present, there is no doubt that a new coronavirus SARS-CоV-2 is the dominant cause of pericarditis. However, such non-infectious causes as systemic inflammatory diseases, paraneoplasic diseases and postpericardiotomy syndromes remain relevant, and require a differentiated therapeutic strategy. For a better understanding of the parameters for a treatment regimen choice, a systematic review considers the pathogenesis of pericarditis development, taking into account modern ideas about infectious and immune mechanisms, as well as a high probability of SARS-CоV-2 virus combination with all the other existing causes. Particular attention is paid to publications on the diagnosis in pandemic conditions, and the effectiveness of pericarditis therapy regimens for inflammation of the heart structures associated with COVID-19. A literature review has been carried out with the use of the medical resources PubMed, Google Scholar, UpToDate, including publications dated from 01.1990 to 09.2022, and concerning the issues of differentiated therapy of pericarditis with various anti-inflammatory drugs.

перикардиттерапиядиагностикаSARS-COV-2COVID-19pericarditistherapydiagnosticsSARS-COV-2COVID-19ReferencesAdler Y., Charron P., Imazio M., Badano L., Barón-Esquivias G., Bogaert J., Brucato A., Gueret P., Klingel K., Lionis C., Maisch B., Mayosi B., Pavie A., Ristic A.D., Sabaté Tenas M., Seferovic P., Swedberg K., Tomkowski W.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2015;36(42):2921–2964. DOI: 10.1093/eurheartj/ehv318Adler Y., Charron P., Imazio M., Badano L., Barón-Esquivias G., Bogaert J., Brucato A., Gueret P., Klingel K., Lionis C., Maisch B., Mayosi B., Pavie A., Ristic A.D., Sabaté Tenas M., Seferovic P., Swedberg K., Tomkowski W.; ESC Scientific Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2015;36(42):2921–2964. DOI: 10.1093/eurheartj/ehv318Сукмарова З.Н., Симоненко В.Б., Ибрагимова Ф.М., Демьяненко А.В. Экссудативный перикардит как новый специфичный симптом SARS-CoV-2: проспективное исследование «случай–контроль». Клиническая медицина. 2021;99(3):192–197. DOI: 10.30629/0023-2149-2021-99-3-192-197Sukmarova Z.N., Simonenko V.B., Ibragimova F.M., Demyanenko A.V. Pericardial eff usion as a new specifi c symptom of SARS-CoV-2. Clinical Medicine. 2021;99(3):192–197. (In Russian). DOI: 10.30629/0023-2149-2021-99-3-192-197Sukmarova Z., Saidova M.A. Echocardiographic phenomenon of pericarditis in patients with severe COVID-19 pneumonia. One-year observation, European Heart Journal — Cardiovascular Imaging. 2022;23(1):jeab289.278. DOI: 10.1093/ehjci/jeab289.278Sukmarova Z., Saidova M.A. Echocardiographic phenomenon of pericarditis in patients with severe COVID-19 pneumonia. One-year observation, European Heart Journal — Cardiovascular Imaging. 2022;23(1):jeab289.278. DOI: 10.1093/ehjci/jeab289.278Сукмарова З.Н., Саидова М.А., Овчинников Ю.В. Экссудативный перикардит в патогенезе нарушений ритма сердца при COVID-19: серия клинических случаев. Кардиоваскулярная терапия и профилактика. 2022;21(2):3021. DOI:10.15829/1728-8800-2022-3021Sukmarova Z.N., Saidova M.A., Ovchinnicov Yu.V. Effusive pericarditis in the pathogenesis of cardiac arrhythmias in COVID-19: a case series. Cardiovascular Therapy and Prevention. 2022;21(2):3021. (In Russian). DOI:10.15829/1728-8800-2022-3021Насонов Е.Л. Российские клинические рекомендации. Ревматология. Москва, ГЭОТАР-Медиа, 2017:464. ISBN 978-5-9704-4261-6Nasonov E.L. Russian clinical guidelines. Rheumatology. Moscow, GEOTAR-Media, 2017:464. (In Russian). ISBN 978-5-9704-4261-6Furqan M.M., Verma B.R., Cremer P.C., Imazio M., Klein A.L. Pericardial diseases in COVID19: a contemporary review. Curr. Cardiol. Rep. 2021;23(7):90. DOI: 10.1007/s11886-021-01519-xFurqan M.M., Verma B.R., Cremer P.C., Imazio M., Klein A.L. Pericardial diseases in COVID19: a contemporary review. Curr. Cardiol. Rep. 2021;23(7):90. DOI: 10.1007/s11886-021-01519-xImazio M., Hoit B.D. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int. J. Cardiol. 2013;168:648–652. DOI: 10.1016/j.ijcard.2012.09.052Imazio M., Hoit B.D. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int. J. Cardiol. 2013;168:648–652. DOI: 10.1016/j.ijcard.2012.09.052Gouriet F., Levy P.Y., Casalta J.P., Zandotti C., Collart F., Lepidi H., Cautela J., Bonnet J.L., Thuny F., Habib G., Raoult D. Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. Am. J. Med. 2015;128(7):784.e1–8. DOI: 10.1016/j.amjmed.2015.01.040Gouriet F., Levy P.Y., Casalta J.P., Zandotti C., Collart F., Lepidi H., Cautela J., Bonnet J.L., Thuny F., Habib G., Raoult D. Etiology of Pericarditis in a Prospective Cohort of 1162 Cases. Am. J. Med. 2015;128(7):784.e1–8. DOI: 10.1016/j.amjmed.2015.01.040Basso C., Leone O., Rizzo S., De Gaspari M., van der Wal A.C., Aubry M.C., Bois M.C., Lin P.T., Maleszewski J.J., Stone J.R. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur. Heart J. 2020;41(39):3827–3835. DOI: 10.1093/eurheartj/ehaa664Basso C., Leone O., Rizzo S., De Gaspari M., van der Wal A.C., Aubry M.C., Bois M.C., Lin P.T., Maleszewski J.J., Stone J.R. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur. Heart J. 2020;41(39):3827–3835. DOI: 10.1093/eurheartj/ehaa664Huang L., Zhao P., Tang D., Zhu T., Han R., Zhan C., Liu W., Zeng H., Tao Q., Xia L. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. JACC Cardiovasc. Imaging. 2020;13(11):2330–2339. DOI: 10.1016/j.jcmg.2020.05.004Huang L., Zhao P., Tang D., Zhu T., Han R., Zhan C., Liu W., Zeng H., Tao Q., Xia L. Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging. JACC Cardiovasc. Imaging. 2020;13(11):2330–2339. DOI: 10.1016/j.jcmg.2020.05.004Libby P., Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020;41(32):3038–44. DOI: 10.1093/eurheartj/ehaa623Libby P., Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020;41(32):3038–44. DOI: 10.1093/eurheartj/ehaa623Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013;13:397–411. DOI: 10.1038/nri3452Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013;13:397–411. DOI: 10.1038/nri3452Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020;17:259–60. DOI: 10.1038/s41569-020-0360-5Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020;17:259–60. DOI: 10.1038/s41569-020-0360-5Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–8. DOI: 10.1007/s00134-020-05991-xRuan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46:846–8. DOI: 10.1007/s00134-020-05991-xChen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5):2620–9. DOI: 10.1172/JCI137244Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5):2620–9. DOI: 10.1172/JCI137244Fernández-Lázaro D., Sánchez-Serrano N., Mielgo-Ayuso J., García-Hernández J.L., González-Bernal J.J., Seco-Calvo J. Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic? J. Clin. Med. 2021;10(24):5799. DOI: 10.3390/jcm10245799Fernández-Lázaro D., Sánchez-Serrano N., Mielgo-Ayuso J., García-Hernández J.L., González-Bernal J.J., Seco-Calvo J. Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic? J. Clin. Med. 2021;10(24):5799. DOI: 10.3390/jcm10245799Puntmann V.O., Martin S., Shchendrygina A., Hoffmann J., Ka M.M., Giokoglu E., Vanchin B., Holm N., Karyou A., Laux G.S., Arendt C., De Leuw P., Zacharowski K., Khodamoradi Y., Vehreschild M.J.G.T., Rohde G., Zeiher A.M., Vogl T.J., Schwenke C., Nagel E. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 2022. DOI: 10.1038/s41591-022-02000-0Puntmann V.O., Martin S., Shchendrygina A., Hoffmann J., Ka M.M., Giokoglu E., Vanchin B., Holm N., Karyou A., Laux G.S., Arendt C., De Leuw P., Zacharowski K., Khodamoradi Y., Vehreschild M.J.G.T., Rohde G., Zeiher A.M., Vogl T.J., Schwenke C., Nagel E. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 2022. DOI: 10.1038/s41591-022-02000-0Puntmann V. O., D’Cruz D., Smith Z., Pastor A., Choong P., Voigt T., Carr-White G., Sangle S., Schaeffter T., Nagel E. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ. Cardiovasc. Imaging. 2013;6:295–301. DOI: 10.1161/CIRCIMAGING.112.000151Puntmann V. O., D’Cruz D., Smith Z., Pastor A., Choong P., Voigt T., Carr-White G., Sangle S., Schaeffter T., Nagel E. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ. Cardiovasc. Imaging. 2013;6:295–301. DOI: 10.1161/CIRCIMAGING.112.000151Carubbi F., Alunno A., Leone S., Di Gregorio N., Mancini B., Viscido A., Del Pinto R., Cicogna S., Grassi D., Ferri C. Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID? Viruses. 2021;13(10):1997. DOI: 10.3390/v13101997Carubbi F., Alunno A., Leone S., Di Gregorio N., Mancini B., Viscido A., Del Pinto R., Cicogna S., Grassi D., Ferri C. Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID? Viruses. 2021;13(10):1997. DOI: 10.3390/v13101997Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–70. DOI: 10.1038/s41577-020-0308-3Cao X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269–70. DOI: 10.1038/s41577-020-0308-3Rodrigues T.S, de Sá KSG., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gonçalves A.V., Perucello D.B., Andrade W.A., Castro R., Veras F.P., Toller-Kawahisa J.E., Nascimento D.C., de Lima M.H.F., Silva CMS., Caetite D.B., Martins R.B., Castro I.A., Pontelli M.C., de Barros F.C., do Amaral N.B., Giannini M.C., Bonjorno L.P., Lopes MIF., Santana R.C., Vilar F.C., Auxiliadora-Martins M., Luppino-Assad R., de Almeida SCL., de Oliveira F.R., Batah S.S., Siyuan L., Benatti M.N., Cunha T.M., Alves-Filho J.C., Cunha F.Q., Cunha L.D., Frantz F.G., Kohlsdorf T., Fabro A.T., Arruda E., de Oliveira RDR., Louzada-Junior P., Zamboni D.S. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218(3):e20201707. DOI: 10.1084/jem.20201707Rodrigues T.S, de Sá KSG., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Gonçalves A.V., Perucello D.B., Andrade W.A., Castro R., Veras F.P., Toller-Kawahisa J.E., Nascimento D.C., de Lima M.H.F., Silva CMS., Caetite D.B., Martins R.B., Castro I.A., Pontelli M.C., de Barros F.C., do Amaral N.B., Giannini M.C., Bonjorno L.P., Lopes MIF., Santana R.C., Vilar F.C., Auxiliadora-Martins M., Luppino-Assad R., de Almeida SCL., de Oliveira F.R., Batah S.S., Siyuan L., Benatti M.N., Cunha T.M., Alves-Filho J.C., Cunha F.Q., Cunha L.D., Frantz F.G., Kohlsdorf T., Fabro A.T., Arruda E., de Oliveira RDR., Louzada-Junior P., Zamboni D.S. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218(3):e20201707. DOI: 10.1084/jem.20201707Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D.S., Cerini M., Farina D., Gavazzi E., Maroldi R., Adamo M., Ammirati E., Sinagra G., Lombardi C.M., Metra M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2019;2020(7):819–24. DOI: 10.1001/jamacardio.2020.1096Inciardi R.M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D.S., Cerini M., Farina D., Gavazzi E., Maroldi R., Adamo M., Ammirati E., Sinagra G., Lombardi C.M., Metra M. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2019;2020(7):819–24. DOI: 10.1001/jamacardio.2020.1096Tam L.S., Tanaka Y., Handa R., Chang C.C., Cheng Y.K., Isalm N., Li M., Lorenzo J.P., Song Y.W., Yamamoto K., Zeng X., Haq S.A. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis. 2020;23(6):717–722. DOI:10.1111/1756-185X.13863Tam L.S., Tanaka Y., Handa R., Chang C.C., Cheng Y.K., Isalm N., Li M., Lorenzo J.P., Song Y.W., Yamamoto K., Zeng X., Haq S.A. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis. 2020;23(6):717–722. DOI:10.1111/1756-185X.13863Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3Buckley L.F., Viscusi M.M., Van Tassell B.W., Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur. Heart J. Cardiovasc. Pharmacother. 2018;4(1):46–53. DOI: 10.1093/ehjcvp/pvx018Buckley L.F., Viscusi M.M., Van Tassell B.W., Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur. Heart J. Cardiovasc. Pharmacother. 2018;4(1):46–53. DOI: 10.1093/ehjcvp/pvx018Lazaros G., Antonopoulos A.S., Lazarou E., Vlachopoulos C., Vogiatzi G., Vassilopoulos D., Tousoulis D. Age- and sex-based differences in patients with acute pericarditis. Eur. J. Clin. Invest. 2021;51(3):e13392. DOI: 10.1111/eci.13392Lazaros G., Antonopoulos A.S., Lazarou E., Vlachopoulos C., Vogiatzi G., Vassilopoulos D., Tousoulis D. Age- and sex-based differences in patients with acute pericarditis. Eur. J. Clin. Invest. 2021;51(3):e13392. DOI: 10.1111/eci.13392Imazio M., Gaita F. Acute and recurrent pericarditis. Cardiol. Clin. 2017;35:505–513. DOI: 10.1016/j.ccl.2017.07.004Imazio M., Gaita F. Acute and recurrent pericarditis. Cardiol. Clin. 2017;35:505–513. DOI: 10.1016/j.ccl.2017.07.004Bonnefoy E., Godon P., Kirkorian G., Fatemi M., Chevalier P., Touboul P. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur. Heart J. 2000;21:832–6. DOI: 10.1053/euhj.1999.1907Bonnefoy E., Godon P., Kirkorian G., Fatemi M., Chevalier P., Touboul P. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur. Heart J. 2000;21:832–6. DOI: 10.1053/euhj.1999.1907Diaz-Arocutipa C., Saucedo-Chinchay J., Imazio M. Pericarditis in patients with COVID-19: a systematic review. J. Cardiovasc. Med. (Hagerstown). 2021;22(9):693–700. DOI: 10.2459/JCM.0000000000001202Diaz-Arocutipa C., Saucedo-Chinchay J., Imazio M. Pericarditis in patients with COVID-19: a systematic review. J. Cardiovasc. Med. (Hagerstown). 2021;22(9):693–700. DOI: 10.2459/JCM.0000000000001202Shah Z.S., Kumar S.A., Patel A.A. Myocarditis and pericarditis in patients with COVID-19. Heart Views. 2020;21(3):209. DOI: 10.4103/HEARTVIEWSShah Z.S., Kumar S.A., Patel A.A. Myocarditis and pericarditis in patients with COVID-19. Heart Views. 2020;21(3):209. DOI: 10.4103/HEARTVIEWSImazio M., Brucato A., Lazaros G., Andreis A., Scarsi M., Klein A., De Ferrari G.M., Adler Y. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J. Cardiovasc. Med. (Hagerstown). 2020;21(9):625–629. DOI: 10.2459/JCM.0000000000001059Imazio M., Brucato A., Lazaros G., Andreis A., Scarsi M., Klein A., De Ferrari G.M., Adler Y. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J. Cardiovasc. Med. (Hagerstown). 2020;21(9):625–629. DOI: 10.2459/JCM.0000000000001059Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H., Yang B., Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10. DOI: 10.1001/jamacardio.2020.0950Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., Huang H., Yang B., Huang C. Association of cardiac injury with mortality in hospitalized patients with COVID19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802–10. DOI: 10.1001/jamacardio.2020.0950Cizgici A.Y., Zencirkiran A.H., Yildiz M. COVID-19 myopericarditis: IT should be kept in mind in today’s conditions. Am. J. Emerg. Med. 2020;38(7):1547.e5–6. DOI: 10.1016/j.ajem.2020.04.080Cizgici A.Y., Zencirkiran A.H., Yildiz M. COVID-19 myopericarditis: IT should be kept in mind in today’s conditions. Am. J. Emerg. Med. 2020;38(7):1547.e5–6. DOI: 10.1016/j.ajem.2020.04.080Klein A.L., Abbara S., Agler D.A., Appleton C.P., Asher C.R., Hoit B., Hung J., Garcia M.J., Kronzon I., Oh J.K., Rodriguez E.R., Schaff H.V., Schoenhagen P., Tan C.D., White R.D. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J. Am. Soc. Echocardiogr. 2013;26:965–1012.e15. DOI: 10.1016/j.echo.2013.06.023Klein A.L., Abbara S., Agler D.A., Appleton C.P., Asher C.R., Hoit B., Hung J., Garcia M.J., Kronzon I., Oh J.K., Rodriguez E.R., Schaff H.V., Schoenhagen P., Tan C.D., White R.D. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. J. Am. Soc. Echocardiogr. 2013;26:965–1012.e15. DOI: 10.1016/j.echo.2013.06.023Cosyns B., Plein S., Nihoyanopoulos P., Smiseth O., Achenbach S., Andrade M.J., Pepi M., Ristic A., Imazio M., Paelinck B., Lancellotti P.; on behalf of the European Association of Cardiovascular Imaging (EACVI) and European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur. Heart J. Cardiovasc Imaging. 2014;16:12–31. DOI: 10.1093/ehjci/jeu128Cosyns B., Plein S., Nihoyanopoulos P., Smiseth O., Achenbach S., Andrade M.J., Pepi M., Ristic A., Imazio M., Paelinck B., Lancellotti P.; on behalf of the European Association of Cardiovascular Imaging (EACVI) and European Society of Cardiology Working Group (ESC WG) on Myocardial and Pericardial diseases. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur. Heart J. Cardiovasc Imaging. 2014;16:12–31. DOI: 10.1093/ehjci/jeu128Vecchie A., Chiabrando J.G., Dell M.S., Bonaventura A., Mauro A.G., Wohlford G., Van Tassell B.W., Berrocal D.H., Montecucco F., Beutler A., Paolini J.F., Gal T.S., Abbate A. Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America. Chest. 2020;158(6):2556–67. DOI: 10.1016/j.chest.2020.07.039Vecchie A., Chiabrando J.G., Dell M.S., Bonaventura A., Mauro A.G., Wohlford G., Van Tassell B.W., Berrocal D.H., Montecucco F., Beutler A., Paolini J.F., Gal T.S., Abbate A. Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America. Chest. 2020;158(6):2556–67. DOI: 10.1016/j.chest.2020.07.039Imazio M., Brucato A., Maestroni S., Cumetti D., Dominelli A., Natale G., Trinchero R. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092–7. DOI: 10.1161/CIRCULATIONAHA.110.986372Imazio M., Brucato A., Maestroni S., Cumetti D., Dominelli A., Natale G., Trinchero R. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092–7. DOI: 10.1161/CIRCULATIONAHA.110.986372Mantovani A., Dinarello C.A., Molgora M., Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50:778–795. DOI: 10.1016/j.immuni.2019.03.012Mantovani A., Dinarello C.A., Molgora M., Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50:778–795. DOI: 10.1016/j.immuni.2019.03.012Nigrovic P.A. Interleukin 1 inhibitors: Biology, principles of use, and adverse events. [Electronic resource]. URL: www.uptodate.com (6 January 2020).Nigrovic P.A. Interleukin 1 inhibitors: Biology, principles of use, and adverse events. [Electronic resource]. URL: www.uptodate.com (6 January 2020).Alraies M.C., AlJaroudi W., Yarmohammadi H., Yingchoncharoen T., Schuster A., Senapati A., Tariq M., Kwon D., Griffin B.P., Klein A.L. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am. J. Cardiol. 2015;115:542–547. DOI: 10.1016/j.amjcard.2014.11.041Alraies M.C., AlJaroudi W., Yarmohammadi H., Yingchoncharoen T., Schuster A., Senapati A., Tariq M., Kwon D., Griffin B.P., Klein A.L. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am. J. Cardiol. 2015;115:542–547. DOI: 10.1016/j.amjcard.2014.11.041Imazio M., Demichelis B., Parrini I., Cecchi E., Pomari F., Demarie D., Gaschino G., Ghisio A., Belli R., Trinchero R. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am. J. Cardiol. 2004;94:973–975. DOI: 10.1016/j.amjcard.2004.06.046Imazio M., Demichelis B., Parrini I., Cecchi E., Pomari F., Demarie D., Gaschino G., Ghisio A., Belli R., Trinchero R. Recurrent pain without objective evidence of disease in patients with previous idiopathic or viral acute pericarditis. Am. J. Cardiol. 2004;94:973–975. DOI: 10.1016/j.amjcard.2004.06.046Imazio M., Pivetta E., Palacio Restrepo S., Sormani P., Pedrotti P., Quarta G., Brucato A., Bubbico E., Dal Corso M., Milazzo A., Quattrocchi G., Andriani M., Lobetti Bodoni L., Davini O., Sironi S., Giannattasio C., Giustetto C., Bogaert J., Adler Y., Bucciarelli Ducci C., De Ferrari G.M. Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am. J. Cardiol. 2020;125:146–151. DOI: 10.1016/j.amjcard.2019.09.026Imazio M., Pivetta E., Palacio Restrepo S., Sormani P., Pedrotti P., Quarta G., Brucato A., Bubbico E., Dal Corso M., Milazzo A., Quattrocchi G., Andriani M., Lobetti Bodoni L., Davini O., Sironi S., Giannattasio C., Giustetto C., Bogaert J., Adler Y., Bucciarelli Ducci C., De Ferrari G.M. Usefulness of cardiac magnetic resonance for recurrent pericarditis. Am. J. Cardiol. 2020;125:146–151. DOI: 10.1016/j.amjcard.2019.09.026Kumar A., Sato K., Yzeiraj E., Betancor J., Lin L., Tamarappoo B.K., Kwon D.H., Hachamovitch R., Klein A.L. Quantitative pericardial delayed hyperenhancement informs clinical course in recurrent pericarditis. JACC Cardiovasc. Imaging. 2017;10(11):1337–1346. DOI: 10.1016/j.jcmg.2016.10.020Kumar A., Sato K., Yzeiraj E., Betancor J., Lin L., Tamarappoo B.K., Kwon D.H., Hachamovitch R., Klein A.L. Quantitative pericardial delayed hyperenhancement informs clinical course in recurrent pericarditis. JACC Cardiovasc. Imaging. 2017;10(11):1337–1346. DOI: 10.1016/j.jcmg.2016.10.020Kumar S., Khubber S., Reyaldeen R., Agrawal A., Cremer P.C., Imazio M., Kwon D.H., Klein A.L. Advances in Imaging and Targeted Therapies for Recurrent Pericarditis: A Review. JAMA Cardiol. 2022 Aug 17. DOI: 10.1001/jamacardio.2022.2584Kumar S., Khubber S., Reyaldeen R., Agrawal A., Cremer P.C., Imazio M., Kwon D.H., Klein A.L. Advances in Imaging and Targeted Therapies for Recurrent Pericarditis: A Review. JAMA Cardiol. 2022 Aug 17. DOI: 10.1001/jamacardio.2022.2584Chetrit M., Xu B., Kwon D.H., Ramchand J., Rodriguez R.E., Tan C.D., Jellis C.L., Johnston D.R., Renapurkar R.D., Cremer P.C., Klein A.L. Imaging-guided therapies for pericardial diseases. JACC Cardiovasc. Imaging. 2020;13(6):1422–1437. DOI: 10.1016/j.jcmg.2019.08.027Chetrit M., Xu B., Kwon D.H., Ramchand J., Rodriguez R.E., Tan C.D., Jellis C.L., Johnston D.R., Renapurkar R.D., Cremer P.C., Klein A.L. Imaging-guided therapies for pericardial diseases. JACC Cardiovasc. Imaging. 2020;13(6):1422–1437. DOI: 10.1016/j.jcmg.2019.08.027Xu B., Kwon D.H., Klein A.L. Imaging of the pericardium: a multimodality cardiovascular imaging update. Cardiol. Clin. 2017;35:491–503. DOI: 10.1016/j.ccl.2017.07.003Xu B., Kwon D.H., Klein A.L. Imaging of the pericardium: a multimodality cardiovascular imaging update. Cardiol. Clin. 2017;35:491–503. DOI: 10.1016/j.ccl.2017.07.003Wang Z.J., Reddy G.P., Gotway M.B., Yeh B.M., Hetts S.W., Higgins C.B.C.T. CT and MR imaging of pericardial disease. Radiographics. 2003;23(1):S167–S180. DOI: 10.1148/rg.23si035504Wang Z.J., Reddy G.P., Gotway M.B., Yeh B.M., Hetts S.W., Higgins C.B.C.T. CT and MR imaging of pericardial disease. Radiographics. 2003;23(1):S167–S180. DOI: 10.1148/rg.23si035504Chiabrando J.G., Bonaventura A., Vecchié A., Wohlford G.F., Mauro A.G., Jordan J.H., Grizzard J.D., Montecucco F., Berrocal D.H., Brucato A., Imazio M., Abbate A. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J. Am. Col.l Cardiol. 2020;75:76. DOI: 10.1016/j.jacc.2019.11.021Chiabrando J.G., Bonaventura A., Vecchié A., Wohlford G.F., Mauro A.G., Jordan J.H., Grizzard J.D., Montecucco F., Berrocal D.H., Brucato A., Imazio M., Abbate A. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J. Am. Col.l Cardiol. 2020;75:76. DOI: 10.1016/j.jacc.2019.11.021Boniface N., Kley J., Lisko J., Mikolich B., Mikolich J.R. Non-cardiac chest pain: Is it really? Circulation. 2014;130:A12863Boniface N., Kley J., Lisko J., Mikolich B., Mikolich J.R. Non-cardiac chest pain: Is it really? Circulation. 2014;130:A12863Puntmann V.O., Carerj L., Wieters I., Fahim M., Arendt C., Hoffmann J., Shchendrygina A., Escher F., Vasa-Nicotera M., Zeiher A.M., Vehreschild M., Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. DOI: 10.1001/jamacardio.2020.3557Puntmann V.O., Carerj L., Wieters I., Fahim M., Arendt C., Hoffmann J., Shchendrygina A., Escher F., Vasa-Nicotera M., Zeiher A.M., Vehreschild M., Nagel E. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. DOI: 10.1001/jamacardio.2020.3557Imazio M., Brucato A., Derosa F.G., Lestuzzi C., Bombana E., Scipione F., Leuzzi S., Cecchi E., Trinchero R., Adler Y. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J. Cardiovasc. Med. (Hagerstown). 2009;10(3):217–30. DOI: 10.2459/JCM.0b013e328322f9b1Imazio M., Brucato A., Derosa F.G., Lestuzzi C., Bombana E., Scipione F., Leuzzi S., Cecchi E., Trinchero R., Adler Y. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J. Cardiovasc. Med. (Hagerstown). 2009;10(3):217–30. DOI: 10.2459/JCM.0b013e328322f9b1Mager A., Berger D., Ofek H., Hammer Y., Iakobishvili Z., Kornowski R. Prodromal symptoms predict myocardial involvement in patients with acute idiopathic pericarditis. Int. J. Cardiol. 2018;270:197–199. DOI: 10.1016/j.ijcard.2018.05.128Mager A., Berger D., Ofek H., Hammer Y., Iakobishvili Z., Kornowski R. Prodromal symptoms predict myocardial involvement in patients with acute idiopathic pericarditis. Int. J. Cardiol. 2018;270:197–199. DOI: 10.1016/j.ijcard.2018.05.128Imazio M., Belli R., Brucato A., Cemin R., Ferrua S., Beqaraj F., Demarie D., Ferro S., Forno D., Maestroni S., Cumetti D., Varbella F., Trinchero R., Spodick D.H., Adler Y. Efcacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014.383:2232–2237. DOI: 10.1016/S0140-6736(13)62709-9Imazio M., Belli R., Brucato A., Cemin R., Ferrua S., Beqaraj F., Demarie D., Ferro S., Forno D., Maestroni S., Cumetti D., Varbella F., Trinchero R., Spodick D.H., Adler Y. Efcacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014.383:2232–2237. DOI: 10.1016/S0140-6736(13)62709-9Krasic S., Prijic S., Ninic S., Borovic R., Petrovic G., Stajevic M., Nesic D., Dizdarevic I., Djordjevic N., Vukomanovic V. Predictive factors of recurrence after pediatric acute pericarditis. J. Pediatr. (Rio J). 2020;29:S0021-7557(20)30190-XKrasic S., Prijic S., Ninic S., Borovic R., Petrovic G., Stajevic M., Nesic D., Dizdarevic I., Djordjevic N., Vukomanovic V. Predictive factors of recurrence after pediatric acute pericarditis. J. Pediatr. (Rio J). 2020;29:S0021-7557(20)30190-XSoler-Soler J., Sagristà-Sauleda J., Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364–1368. DOI: 10.1136/hrt.2003.026120Soler-Soler J., Sagristà-Sauleda J., Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364–1368. DOI: 10.1136/hrt.2003.026120Andreis A., Imazio M., Casula M., Avondo S., Brucato A. Recurrent pericarditis: an update on diagnosis and management. Intern. Emerg. Med. 2021;16(3):551–558. DOI: 10.1007/s11739-021-02639-6Andreis A., Imazio M., Casula M., Avondo S., Brucato A. Recurrent pericarditis: an update on diagnosis and management. Intern. Emerg. Med. 2021;16(3):551–558. DOI: 10.1007/s11739-021-02639-6Bouriche F., Toro A., Negre V., Yvorra S. Acute Pericarditis: Aetiologic Diagnosis and Practical Aspect of the Management. Curr. Probl. Cardiol. 2021;46(4):100769. DOI: 10.1016/j.cpcardiol.2020.100769Bouriche F., Toro A., Negre V., Yvorra S. Acute Pericarditis: Aetiologic Diagnosis and Practical Aspect of the Management. Curr. Probl. Cardiol. 2021;46(4):100769. DOI: 10.1016/j.cpcardiol.2020.100769Bhatia R.T., Marwaha S., Malhotra A. Exercise in the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of sports cardiology & exercise of the European Association of Preventive Cardiology (EAPC) Eur. J. Prev. Cardiol. 2020;27(12):1242–1251. DOI: 10.1177/2047487320930596Bhatia R.T., Marwaha S., Malhotra A. Exercise in the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) era: a question and answer session with the experts endorsed by the section of sports cardiology & exercise of the European Association of Preventive Cardiology (EAPC) Eur. J. Prev. Cardiol. 2020;27(12):1242–1251. DOI: 10.1177/2047487320930596Vecchié A., Del Buono M.G., Chiabrando G.J., Dentali F., Abbate A., Bonaventura A. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Curr. Cardiol. Rep. 2021;23(11):157. DOI: 10.1007/s11886-021-01589-xVecchié A., Del Buono M.G., Chiabrando G.J., Dentali F., Abbate A., Bonaventura A. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Curr. Cardiol. Rep. 2021;23(11):157. DOI: 10.1007/s11886-021-01589-xImazio M., Andreis A., Piroli F., Lazaros G., Gattorno M., Lewinter M., Klein A.L., Brucato A. Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis. Heart. 2021:heartjnl-2020-318869. DOI: 10.1136/heartjnl-2020-318869Imazio M., Andreis A., Piroli F., Lazaros G., Gattorno M., Lewinter M., Klein A.L., Brucato A. Anti-interleukin 1 agents for the treatment of recurrent pericarditis: a systematic review and meta-analysis. Heart. 2021:heartjnl-2020-318869. DOI: 10.1136/heartjnl-2020-318869Brucato A., Emmi G., Cantarini L., Di Lenarda A., Gattorno M., Lopalco G., Marcolongo R., Imazio M., Martini A., Prisco D. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern. Emerg. Med. 2018;13(4):475–489. DOI: 10.1007/s11739-018-1842-xBrucato A., Emmi G., Cantarini L., Di Lenarda A., Gattorno M., Lopalco G., Marcolongo R., Imazio M., Martini A., Prisco D. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Intern. Emerg. Med. 2018;13(4):475–489. DOI: 10.1007/s11739-018-1842-xConte E., Agalbato C., Lauri G, Mushtaq S., Cia A.D., Bonomi A., Guglielmo M., Baggiano A., Gaudenzi-Asinelli M., Colombo G., Sforza C., Agostoni P., Tamborini G., Assanelli E., Pontone G., Pepi M., Brucato A., Andreini D. Cardiac MRI after first episode of acute pericarditis: a pilot study for better identification of high risk patients. Int. J. Cardiol. 2022;354:63–67. DOI: 10.1016/j.ijcard.2022.03.007Conte E., Agalbato C., Lauri G, Mushtaq S., Cia A.D., Bonomi A., Guglielmo M., Baggiano A., Gaudenzi-Asinelli M., Colombo G., Sforza C., Agostoni P., Tamborini G., Assanelli E., Pontone G., Pepi M., Brucato A., Andreini D. Cardiac MRI after first episode of acute pericarditis: a pilot study for better identification of high risk patients. Int. J. Cardiol. 2022;354:63–67. DOI: 10.1016/j.ijcard.2022.03.007Cremer P., Lin D., Wheeler A., Abbate A. Cardiac magnetic resonance imaging for guiding decision-making on treatment duration: data from rhapsody, a phase 3 clinical trial of rilonacept in recurrent pericarditis. J. Am. Coll. Cardiol. 2021;77(18) (suppl 1):1302. DOI: 10.1016/S0735-1097(21)02660-7Cremer P., Lin D., Wheeler A., Abbate A. Cardiac magnetic resonance imaging for guiding decision-making on treatment duration: data from rhapsody, a phase 3 clinical trial of rilonacept in recurrent pericarditis. J. Am. Coll. Cardiol. 2021;77(18) (suppl 1):1302. DOI: 10.1016/S0735-1097(21)02660-7Imazio M., Cecchi E., Demichelis B., Ierna S., Demarie D., Ghisio A., Pomari F., Coda L., Belli R., Trinchero R. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739–44. DOI: 10.1161/CIRCULATIONAHA.106.662114Imazio M., Cecchi E., Demichelis B., Ierna S., Demarie D., Ghisio A., Pomari F., Coda L., Belli R., Trinchero R. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739–44. DOI: 10.1161/CIRCULATIONAHA.106.662114Moore N., Bosco-Levy P., Thurin N., Blin P., Droz-Perroteau C. NSAIDs and COVID-19: A Systematic Review and Meta-Аnalysis. Dru. DOI: 10.1001/jamacardio.2022.2584g. Saf. 2021;44(9):929–938. DOI: 10.1007/s40264-021-01089-5Moore N., Bosco-Levy P., Thurin N., Blin P., Droz-Perroteau C. NSAIDs and COVID-19: A Systematic Review and Meta-Аnalysis. Dru. DOI: 10.1001/jamacardio.2022.2584g. Saf. 2021;44(9):929–938. DOI: 10.1007/s40264-021-01089-5Arunasalam S., Siegel R.J. Rapid resolution of symptomatic acute pericarditis with ketorolac tromethamine: a parenteral nonsteroidal antiinflammatory agent. Am. Heart J. 1993;125:1455.Arunasalam S., Siegel R.J. Rapid resolution of symptomatic acute pericarditis with ketorolac tromethamine: a parenteral nonsteroidal antiinflammatory agent. Am. Heart J. 1993;125:1455.Pope J.E., Anderson J.J., Felson D.T. A metaanalysis of the effects of nonsteroidal antiinflammatory drugs on blood pressure. Arch. Intern. Med. 1993;153:477–84.Pope J.E., Anderson J.J., Felson D.T. A metaanalysis of the effects of nonsteroidal antiinflammatory drugs on blood pressure. Arch. Intern. Med. 1993;153:477–84.Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 1999;106:13S–24S.Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am. J. Med. 1999;106:13S–24S.Imazio M., Cecchi E., Demichelis B., Chinaglia A., Ierna S., Demarie D., Ghisio A., Pomari F., Belli R., Trinchero R. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94(4):498–501. DOI: 10.1136/hrt.2006.104067Imazio M., Cecchi E., Demichelis B., Chinaglia A., Ierna S., Demarie D., Ghisio A., Pomari F., Belli R., Trinchero R. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94(4):498–501. DOI: 10.1136/hrt.2006.104067Wood J.E., Mahnensmith R.L. Pericarditis associated with renal failure: evolution and management. Semin. Dial. 2001;14(1):61–6. DOI: 10.1046/j.1525-139x.2001.00017.xWood J.E., Mahnensmith R.L. Pericarditis associated with renal failure: evolution and management. Semin. Dial. 2001;14(1):61–6. DOI: 10.1046/j.1525-139x.2001.00017.xImazio M., Brucato A., Trinchero R., Spodick D., Adler Y. Individualized therapy for pericarditis. Expert Rev. Cardiovasc. Ther. 2009;7(8):965–75. DOI: 10.1586/erc.09.82Imazio M., Brucato A., Trinchero R., Spodick D., Adler Y. Individualized therapy for pericarditis. Expert Rev. Cardiovasc. Ther. 2009;7(8):965–75. DOI: 10.1586/erc.09.82WHO. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms 2020. [Electronic resource]. URL: https://www.scienceale.rt.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms. Accessed 1 Mar 2021.WHO. Updated: WHO Now Doesn’t Recommend Avoiding Ibuprofen For COVID-19 Symptoms 2020. [Electronic resource]. URL: https://www.scienceale.rt.com/who-recommends-to-avoid-taking-ibuprofen-for-covid-19-symptoms. Accessed 1 Mar 2021.Chen J.S., Alfajaro M.M., Chow R.D., Wei J., Filler R.B., Eisenbarth S.C., Wilen C.B. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J. Virol. 2021;95(7):e00014–21. DOI: 10.1128/JVI.00014-21Chen J.S., Alfajaro M.M., Chow R.D., Wei J., Filler R.B., Eisenbarth S.C., Wilen C.B. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection. J. Virol. 2021;95(7):e00014–21. DOI: 10.1128/JVI.00014-21Chen J.S., Alfajaro M.M., Wei J., Chow R.D., Filler R.B., Eisenbarth S.C. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not afect viral entry or replication. bioRxiv. 2020. DOI: 10.1101/2020.09.24.312769Chen J.S., Alfajaro M.M., Wei J., Chow R.D., Filler R.B., Eisenbarth S.C. Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not afect viral entry or replication. bioRxiv. 2020. DOI: 10.1101/2020.09.24.312769Kelleni M.T. Early use of non-steroidal anti-infammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed. Pharmacother. 2021;133:110982. DOI: 10.1016/j.biopha.2020.110982Kelleni M.T. Early use of non-steroidal anti-infammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed. Pharmacother. 2021;133:110982. DOI: 10.1016/j.biopha.2020.110982Chandan J.S., Zemedikun D.T., Thayakaran R., Byne N., Dhalla S., Acosta-Mena D., Gokhale K.M., Thomas T., Sainsbury C., Subramanian A., Cooper J., Anand A., Okoth K.O., Wang J., Adderley N.J., Taverner T., Denniston A.K., Lord J., Thomas G.N., Buckley C.D., Raza K., Bhala N., Nirantharakumar K., Haroon S. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. Arthritis Rheumatol. 2021;73(5):731–739. DOI: 10.1002/art.41593Chandan J.S., Zemedikun D.T., Thayakaran R., Byne N., Dhalla S., Acosta-Mena D., Gokhale K.M., Thomas T., Sainsbury C., Subramanian A., Cooper J., Anand A., Okoth K.O., Wang J., Adderley N.J., Taverner T., Denniston A.K., Lord J., Thomas G.N., Buckley C.D., Raza K., Bhala N., Nirantharakumar K., Haroon S. Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19. Arthritis Rheumatol. 2021;73(5):731–739. DOI: 10.1002/art.41593Costantino F., Bahier L., Tarancon L.C., Leboime A., Vidal F., Bessalah L., Breban M., D’Agostino M.A. COVID-19 in French patients with chronic infammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Jt. Bone Spine. 2021;88(1):105095. DOI: 10.1016/j.jbspin.2020.105095Costantino F., Bahier L., Tarancon L.C., Leboime A., Vidal F., Bessalah L., Breban M., D’Agostino M.A. COVID-19 in French patients with chronic infammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Jt. Bone Spine. 2021;88(1):105095. DOI: 10.1016/j.jbspin.2020.105095Imazio M., Bobbio M., Cecchi E., Demarie D., Demichelis B., Pomari F., Moratti M., Gaschino G., Giammaria M., Ghisio A., Belli R., Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012. DOI: 10.1161/CIRCULATIONAHA.105.542738Imazio M., Bobbio M., Cecchi E., Demarie D., Demichelis B., Pomari F., Moratti M., Gaschino G., Giammaria M., Ghisio A., Belli R., Trinchero R. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012. DOI: 10.1161/CIRCULATIONAHA.105.542738Berman J., Haffajee C.I., Alpert J.S. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am. Heart J. 1981;101:750Berman J., Haffajee C.I., Alpert J.S. Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am. Heart J. 1981;101:750Lamontagne F., Agoritsas T., MacDonald H., Zeng L., Amin W., Barragan FAJ., Bausch F.J., Burhan E., Calfee C.S., Cecconi M., Chanda D., Dat V.Q., De Sutter A., Du B., Freedman S., Geduld H., Gee P., Gotte M., Harley N., Hashimi M., Hunt B., Jehan F., Kabra S.K., Kanda S., Kim Y.J., Kissoon N., Krishna S., Kuppalli K., Kwizera A., Lado Castro-Rial M., Lisboa T., Lodha R., Mahaka I., Manai H., Mino G., Nsutebu E., Preller J., Pshenichnaya N., Qadir N., Relan P., Sabzwari S., Sarin R., Shankar-Hari M., Sharland M., Shen Y., Ranganathan S.S., Souza J.P., Stegemann M., Swanstrom R., Ugarte S., Uyeki T., Venkatapuram S., Vuyiseka D., Wijewickrama A., Tran L., Zeraatkar D., Bartoszko J.J., Ge L., Brignardello-Petersen R., Owen A., Guyatt G., Diaz J., Kawano-Dourado L., Jacobs M., Vandvik P.O. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. DOI: 10.1136/bmj.m3379Lamontagne F., Agoritsas T., MacDonald H., Zeng L., Amin W., Barragan FAJ., Bausch F.J., Burhan E., Calfee C.S., Cecconi M., Chanda D., Dat V.Q., De Sutter A., Du B., Freedman S., Geduld H., Gee P., Gotte M., Harley N., Hashimi M., Hunt B., Jehan F., Kabra S.K., Kanda S., Kim Y.J., Kissoon N., Krishna S., Kuppalli K., Kwizera A., Lado Castro-Rial M., Lisboa T., Lodha R., Mahaka I., Manai H., Mino G., Nsutebu E., Preller J., Pshenichnaya N., Qadir N., Relan P., Sabzwari S., Sarin R., Shankar-Hari M., Sharland M., Shen Y., Ranganathan S.S., Souza J.P., Stegemann M., Swanstrom R., Ugarte S., Uyeki T., Venkatapuram S., Vuyiseka D., Wijewickrama A., Tran L., Zeraatkar D., Bartoszko J.J., Ge L., Brignardello-Petersen R., Owen A., Guyatt G., Diaz J., Kawano-Dourado L., Jacobs M., Vandvik P.O. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379. DOI: 10.1136/bmj.m3379Li A., Garcia-Bengochea Y., Stechel R., Azari B.M. Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report. Eur. Hear J. — Case Rep. 2020;4(FI1):1–6. DOI: 10.1093/ehjcr/ytaa224Li A., Garcia-Bengochea Y., Stechel R., Azari B.M. Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm: a case report. Eur. Hear J. — Case Rep. 2020;4(FI1):1–6. DOI: 10.1093/ehjcr/ytaa224Lange R.A., Hillis L.D. Clinical practice. Acute pericarditis. N Engl J Med. 2004; 351:2195.Lange R.A., Hillis L.D. Clinical practice. Acute pericarditis. N Engl J Med. 2004; 351:2195.Artom G., Koren-Morag N., Spodick D.H., Brucato A., Guindo J., Bayes-de-Luna A., Brambilla G., Finkelstein Y., Granel B., Bayes-Genis A., Schwammenthal E., Adler Y. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur. Heart J. 2005;26(7):723–7. DOI: 10.1093/eurheartj/ehi197Artom G., Koren-Morag N., Spodick D.H., Brucato A., Guindo J., Bayes-de-Luna A., Brambilla G., Finkelstein Y., Granel B., Bayes-Genis A., Schwammenthal E., Adler Y. Pretreatment with corticosteroids attenuates the efficacy of colchicine in preventing recurrent pericarditis: a multi-centre all-case analysis. Eur. Heart J. 2005;26(7):723–7. DOI: 10.1093/eurheartj/ehi197Imazio M., Demichelis B., Parrini I., Cecchi E., Demarie D., Ghisio A., Belli R., Bobbio M., Trinchero R. Management, risk factors, and outcomes in recurrent pericarditis. Am. J. Cardiol. 2005;96(5):736–9. DOI: 10.1016/j.amjcard.2005.04.055Imazio M., Demichelis B., Parrini I., Cecchi E., Demarie D., Ghisio A., Belli R., Bobbio M., Trinchero R. Management, risk factors, and outcomes in recurrent pericarditis. Am. J. Cardiol. 2005;96(5):736–9. DOI: 10.1016/j.amjcard.2005.04.055Lotrionte M., Biondi-Zoccai G., Imazio M., Castagno D., Moretti C., Abbate A., Agostoni P., Brucato A.L., Di Pasquale P., Raatikka M., Sangiorgi G., Laudito A., Sheiban I., Gaita F. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am. Heart J. 2010;160(4):662–70. DOI: 10.1016/j.ahj.2010.06.015Lotrionte M., Biondi-Zoccai G., Imazio M., Castagno D., Moretti C., Abbate A., Agostoni P., Brucato A.L., Di Pasquale P., Raatikka M., Sangiorgi G., Laudito A., Sheiban I., Gaita F. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am. Heart J. 2010;160(4):662–70. DOI: 10.1016/j.ahj.2010.06.015Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. DOI: 10.1016/S0140-6736(20)30317-2Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. DOI: 10.1016/S0140-6736(20)30317-2Peet C.J., Rowczenio D., Omoyinmi E., Papadopoulou C., Mapalo B.R.R., Wood M.R., Capon F., Lachmann H.J. Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. J. Am. Heart Assoc. 2022;11(11):e024931. DOI: 10.1161/JAHA.121.024931Peet C.J., Rowczenio D., Omoyinmi E., Papadopoulou C., Mapalo B.R.R., Wood M.R., Capon F., Lachmann H.J. Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center. J. Am. Heart Assoc. 2022;11(11):e024931. DOI: 10.1161/JAHA.121.024931Imazio M., Brucato A., Cumetti D., Brambilla G., Demichelis B., Ferro S., Maestroni S., Cecchi E., Belli R., Palmieri G., Trinchero R. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation. 2008;118(6):667–71. DOI: 10.1161/CIRCULATIONAHA.107.761064Imazio M., Brucato A., Cumetti D., Brambilla G., Demichelis B., Ferro S., Maestroni S., Cecchi E., Belli R., Palmieri G., Trinchero R. Corticosteroids for recurrent pericarditis: high versus low doses: a nonrandomized observation. Circulation. 2008;118(6):667–71. DOI: 10.1161/CIRCULATIONAHA.107.761064Mainzer G., Zaidman I., Hatib I., Lorber A. Intrapericardial steroid treatment for recurrent pericardial effusion in a patient with acute lymphoblastic Leukaemia. Hematol Oncol. 2011;29(4):220-1. DOI: 10.1002/hon.983Mainzer G., Zaidman I., Hatib I., Lorber A. Intrapericardial steroid treatment for recurrent pericardial effusion in a patient with acute lymphoblastic Leukaemia. Hematol Oncol. 2011;29(4):220-1. DOI: 10.1002/hon.983

The authors declare that there are no conflicts of interest present.